内部人交易记录
首席执行官尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Discover the complete record of transactions filed by Gano Kyle, 首席执行官. Director active across 1 company, notably Neurocrine Biosciences INC. In total, 20 reports have been published. Breakdown: 0 buy · 10 sells. Total volume traded: €1.2m. Activity tracked since 5 January 2022. The latest transaction was disclosed on 12 February 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Gano Kyle
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
4,907 股0Common StockSEC:0001567160-26-000007:0
2,927 股0Common StockSEC:0001567160-26-000005:0
34,588 股@ US$35.990.0076% mcap40.0% 占其流量Common StockSEC:0001567160-26-000002:0
613 股0Common StockSEC:0001567160-25-000008:0
2,566 股0Common StockSEC:0000914475-25-000063:0
1,860 股0Common StockSEC:0000914475-25-000049:0
2,927 股0Common StockSEC:0000914475-25-000025:0
4,812 股@ US$32.993.0% 占其流量Common StockSEC:0000914475-25-000004:0
1,352 股@ US$132.89473.2% 占其流量Common StockSEC:0000914475-24-000072:0
1,600 股@ US$142.20134.1% 占其流量Common StockSEC:0000914475-24-000045:0
1,541 股@ US$140.6963.9% 占其流量Common StockSEC:0000914475-24-000027:0
68,884 股@ US$19.5923.7% 占其流量Common StockSEC:0000914475-24-000007:0
2,132 股@ US$107.40754.1% 占其流量Common StockSEC:0001209191-23-047135:0
1,600 股@ US$105.64223.0% 占其流量Common StockSEC:0001209191-23-007910:0
1,541 股@ US$109.98473.0% 占其流量Common StockSEC:0001209191-23-006275:0
703 股@ US$80.6830.0003% mcap1.8% 占其流量Common StockSEC:0001209191-22-008207:0
28,266 股@ US$8.660.0015% mcap8.1% 占其流量Common StockSEC:0001209191-22-002529:0
1,375 股Common StockSEC:0001209191-16-095849:0
1,625 股Common StockSEC:0001209191-16-092886:0
1,250 股Common StockSEC:0001209191-16-091252:0
About Gano Kyle
Kyle Gano serves as Chief Executive Officer and Chief Business Development Officer at Neurocrine Biosciences Inc. He leads the company's strategic initiatives and oversees the development of new business opportunities. Kyle brings expertise in management and product development, contributing to innovation and growth at Neurocrine.
